The cell analysis market size was exhibited at USD 31.18 billion in 2024 and is projected to hit around USD 80.14 billion by 2034, growing at a CAGR of 9.9% during the forecast period 2024 to 2034.
This growth can be attributed to the increasing prevalence of chronic diseases, advancements in cell analysis technologies, and the growing number of drug discovery activities. Cell analysis has emerged as an important tool for the identification of potential therapies and treatments for chronic diseases. Thus, the increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, autoimmune diseases, neurological disorders, and others can drive the demand for cell analysis. According to the American Cancer Society, over 2 million new cancer cases are expected to be diagnosed in the U.S. in 2024.
The U.S. cell analysis market size is evaluated at USD 8.95 billion in 2024 and is projected to be worth around USD 23.16 billion by 2034, growing at a CAGR of 8.95% from 2024 to 2034.
North America dominated the market and accounted for a 40.3% share in 2024 owing to the large number of drug discovery activities, better access to advanced cell analysis technologies, and presence of key market players, and the high prevalence of chronic diseases in the region. According to the Statistics Canada data, approximately 45.1% of Canadians in 2021 suffered from at least one major chronic disease. Such a high chronic disease prevalence increases the need for advanced and effective treatments, thereby driving market growth.
U.S. Cell Analysis Market Trends
The U.S. cell analysis market is anticipated to witness lucrative growth over the forecast period. This growth can be attributed to the presence of key market players, supportive regulatory framework, and increasing R&D efforts by pharmaceutical and biotechnology companies. Moreover, the U.S. is home to several leading market players, which increases access to cell analysis technology for the country’s pharmaceutical and biotechnology industry. Similarly, these market players launch their advanced technologies in the country, further increasing their adoption and driving the market growth. For instance, in May 2024, Deepcell announced the launch of its REM-I Platform. This platform offers unprecedented insights into cell biology through high-dimensional analysis, scalable single-cell imaging, and cell sorting.
Europe Cell Analysis Market Trends
Europe cell analysis market is projected to witness significant growth driven by factors such as the rising government initiatives and funding for the life science sector, increasing prevalence of cancers, and developing healthcare sector. In May 2024, the UK Chancellor announced USD 808.45 million in funding for the country’s life science industry for various purposes such as improving commercial clinical trials, scientific innovation, increasing the capacity of biological data banks, and incentivizing pension schemes. Such increasing funding and efforts for the development of the region's life science industry are anticipated to drive the market in the region.
Asia Pacific Cell Analysis Market Trends
Asia Pacific cell analysis market is anticipated to witness the fastest growth at a CAGR of 10.87% from 2024 to 2030. The region is expected to witness substantial growth in the market, driven by factors such as increasing investments in healthcare infrastructure, high prevalence of chronic diseases, and increasing clinical trials. According to the American College of Cardiology Foundation data published in June 2021, cardiovascular disease-associated deaths in Asia rose from 5.6 million to 10.8 million from 1990 to 2019 in Asia. Such increasing prevalence of chronic disease. Such increasing prevalence of chronic diseases is expected to drive the demand for cell analysis technologies over the forecast period.
| Report Coverage | Details |
| Market Size in 2025 | USD 34.27 Billion |
| Market Size by 2034 | USD 80.14 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 9.9% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Product & Service, Technique, Process, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Thermo Fisher Scientific, Inc.; Danaher; BD; Merck KGaA; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Miltenyl Biotech; Revvity; New England Biolabs; Avantor, Inc. |
The reagents & consumables segment dominated the market with the largest revenue share of 49.0% in 2024. This can be attributed to the wide range of applications of reagents and consumables, frequent purchases, and increased demand for assay kits. Unlike other cell analysis products and services, reagents & consumables are used in different experiments and for different applications, increasing their purchase frequency. Similarly, the segment consists of a wide range of products addressing the different needs of researchers, which ensures the constant demand for these products throughout the research process, thereby contributing to the segment growth.
The service segment is expected to witness the fastest growth over the forecast period owing to the growing complexity of cell analysis techniques, which might require specialized expertise and solutions. The labs or research institutes may lack the availability of these resources thereby increasing the demand for specialized services. Similarly, the increasing number of CROs offering a wide range of cell analysis services offer alternatives for the researchers to outsource specific services as per their requirements.
The flow cytometry segment dominated the market with the largest revenue share in 2024. This can be attributed to the ability of the flow cytometry process to allow researchers to analyse a large number of cells simultaneously with multiple parameters such as size, shape, granularity, and the presence of specific molecules in or outside the cell surface. Moreover, several market players are developing solutions to enhance the flow cytometry results, which is further contributing to its growth. For instance, in November 2022, Sony Corporation announced the launch of SFA - Life Sciences Cloud Platform. This platform is a flow cytometry data analysis solution which can identify rare cells from a wide variety of cell populations with better efficiency using data obtained from flow cytometers.
The high-content screening segment is expected to witness the fastest growth with a CAGR of 11.21% over the forecast period. High-content screening goes beyond traditional cell analysis techniques by using automated image analysis, artificial intelligence (AI), and machine learning, enabling researchers to extract better insights. Moreover, the ability of high-content screening to analyze a large number of compound and cellular features simultaneously is anticipated to drive its demand over the forecast period.
Cell identification segment dominated the market with the largest revenue share of 4.81% in 2024. Cell analysis is the first step of any downstream analysis, making it an essential process for any study. Moreover, Cell identification has a wide range of applications in immunology, oncology, toxicology, drug discovery, and stem cell research, further increasing its importance. In addition, cell identification, being a generic process, can be done through several methods. This availability of various techniques for cell identification further contributes to its growth.
Single-cell analysis is expected to witness the fastest growth over the forecast period. Single-cell analysis allows researchers to analyze individual cells, revealing the remarkable heterogeneity within a seemingly homogenous group of cells. This hidden diversity can be crucial for cellular function, disease development, and drug response. Moreover, several market players are developing advanced solutions for single-cell analysis, further contributing to the segment growth. For instance, in October 2021, PerkinElmer and Honeycomb Biotechnologies launched the HIVE scRNAseq Solution. This solution advances single-cell analysis by allowing the researchers to capture, store, and analyze fragile cell types.
The pharmaceutical and biotechnology companies segment dominated the market with the largest share of 41.0%. This can be attributed to the increasing drug discovery efforts, high R&D investment capacity, and increasing focus on personalized medicine by these companies. Pharmaceutical and biotechnology companies account for significantly high drug discovery activities. Cell analysis, being a crucial part of drug discovery, is utilized by these companies for various purposes, increasing the segment share of pharmaceutical and biotechnology companies.
Hospitals and clinical testing laboratories are expected to witness the fastest growth over the forecast period. The fast growth can be attributed to the increasing demand for biomarker identification, early disease diagnostics, and disease progression. Cell analysis can help identify specific molecules or cellular characteristics, allowing hospitals to predict a patient's response to a particular treatment. This allows healthcare providers to personalize treatment plans for each patient, improving patient outcomes. Similarly, advanced cell analysis techniques can allow healthcare providers to diagnose diseases more accurately and effectively, further increasing their importance for hospitals and clinical testing laboratories.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the cell analysis market
By Product & Service
By Technique
By Process
By End-use
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers